ArticleAnnals of surgical oncology2026
Patterns of Recurrence in Adenocarcinoma of the Esophagogastric Junction: ERECS Trial Post Hoc Analysis.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ASO Author Reflections: From Recurrence Patterns to Risk-Adapted Care in Esophagogastric Junction Adenocarcinoma.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdenocarcinoma of the esophagogastric junction (AEG) is associated with high recurrence rates despite multimodal therapy. Understanding recurrence patterns and their predictive factors is critical for optimizing risk stratification and guiding therapeutic decision-making.
methodsThis post hoc analysis of the multicenter retrospective ERECS trial included patients who had Siewert type 1 or 2 AEG treated with perioperative chemotherapy (BMT) or neoadjuvant chemoradiotherapy (TMT) followed by Ivor Lewis esophagectomy between January 2018 and December 2022. Uni- and multivariable Fine and Gray regression models identified predictors of recurrence. Overall survival after recurrence (OSAR) was estimated using the Kaplan-Meier method.
resultsOf 455 patients, 7.9% experienced local recurrence (LR) and 36.9% had distant recurrence (DR) during a median follow-up period of 29.8 months. Among the DR patients, 56% had single-site (sDR) and 44% multiple-site (mDR) involvement. Lymph nodes, liver, and lungs were the most frequently involved distant sites. In the multivariable analysis, TMT and mucinous histology independently predicted LR, whereas advanced pathologic stage, poor response to neoadjuvant therapy, and perineural invasion were associated with DR. For sDR, OSAR was better than mDR (12-month OSAR: 62% vs. 42%; p = 0.037).
conclusionsDistant recurrence remains the principal driver of treatment failure in locally advanced AEG. Advanced pathologic stage, poor treatment response, and perineural invasion identify patients at high systemic risk who may benefit from intensified systemic therapy. In this study, post-recurrence survival was significantly better for sDR (which does not fully correspond to oligometastatic disease) than for mDR. Prospective validation of a tailored surveillance strategy for high-risk patients is warranted.
Indexed as
Identifiers
42753058What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.